Santini C, Baiocchi P, Venditti M, Gelfusa V, Tarasi A, Brandimarte C, Serra P
Patologia Medica II-Università degli Studi di Roma La Sapienza, Italy.
J Chemother. 1991 Apr;3(2):121-5. doi: 10.1080/1120009x.1991.11739077.
Intravenous ciprofloxacin at a daily dosage of 400 mg divided in two doses was administered to 19 patients with severe infections caused by ciprofloxacin-susceptible bacteria. These infections included: 11 surgical would infections, 5 soft tissue infections, 2 respiratory tract infections, 1 urinary tract infection. The offending pathogens were: 8 coagulase-negative staphylococci, 3 Staphylococcus aureus, 3 Pseudomonas aeruginosa, 2 Proteus spp., 1 Escherichia coli, 1 Branhamella catarrhalis, 1 Klebsiella ozenae and 1 Serratia liquefaciens. Overall, 17 of 19 infections (89%) showed a satisfactory clinical response to trial therapy (15 cures and 2 improvements). Microbiological eradication was observed in 17 out of 20 isolated pathogens. Emergence of resistance to ciprofloxacin occurred in 1 coagulase-negative Staphylococcus and was associated with clinical failure. No side effects were observed. We conclude that intravenous ciprofloxacin may represent efficacious and safe therapy of severe infections; however close microbiological monitoring seems to be necessary to evaluate the emergence of resistance during quinolone therapy.
对19例由对环丙沙星敏感的细菌引起严重感染的患者，静脉注射环丙沙星，每日剂量400mg，分两次给药。这些感染包括：11例手术伤口感染、5例软组织感染、2例呼吸道感染、1例尿路感染。致病病原体为：8株凝固酶阴性葡萄球菌、3株金黄色葡萄球菌、3株铜绿假单胞菌、2株变形杆菌属、1株大肠杆菌、1株卡他布兰汉菌、1株臭鼻克雷伯菌和1株液化沙雷菌。总体而言，19例感染中有17例（89%）对试验性治疗显示出满意的临床反应（15例治愈，2例好转）。在分离出的20种病原体中，有17种观察到微生物学清除。1株凝固酶阴性葡萄球菌出现对环丙沙星的耐药性，并与临床治疗失败相关。未观察到副作用。我们得出结论，静脉注射环丙沙星可能是治疗严重感染的有效且安全的疗法；然而，似乎有必要进行密切的微生物学监测，以评估喹诺酮治疗期间耐药性的出现情况。
